Prophylactic tenofovir alafenamide for hepatitis B virus reactivation and reactivation‐related hepatitis
-
- Goki Suda
- Departments of Gastroenterology and Hepatology, Graduate School of Medicine Hokkaido University Sapporo Japan
-
- Masaru Baba
- Department of Gastroenterology and Hepatology Japan Community Health Care Organization (JCHO) Hokkaido Hospital Hokkaido Japan
-
- Yoshiya Yamamoto
- Department of Gastroenterology and Hepatology Hakodate City Hospital Hokkaido Japan
-
- Takuya Sho
- Departments of Gastroenterology and Hepatology, Graduate School of Medicine Hokkaido University Sapporo Japan
-
- Koji Ogawa
- Departments of Gastroenterology and Hepatology, Graduate School of Medicine Hokkaido University Sapporo Japan
-
- Megumi Kimura
- Departments of Gastroenterology and Hepatology, Graduate School of Medicine Hokkaido University Sapporo Japan
-
- Shunichi Hosoda
- Departments of Gastroenterology and Hepatology, Graduate School of Medicine Hokkaido University Sapporo Japan
-
- Sonoe Yoshida
- Departments of Gastroenterology and Hepatology, Graduate School of Medicine Hokkaido University Sapporo Japan
-
- Akinori Kubo
- Departments of Gastroenterology and Hepatology, Graduate School of Medicine Hokkaido University Sapporo Japan
-
- Qingjie Fu
- Departments of Gastroenterology and Hepatology, Graduate School of Medicine Hokkaido University Sapporo Japan
-
- Zijian Yang
- Departments of Gastroenterology and Hepatology, Graduate School of Medicine Hokkaido University Sapporo Japan
-
- Yoshimasa Tokuchi
- Departments of Gastroenterology and Hepatology, Graduate School of Medicine Hokkaido University Sapporo Japan
-
- Takashi Kitagataya
- Departments of Gastroenterology and Hepatology, Graduate School of Medicine Hokkaido University Sapporo Japan
-
- Osamu Maehara
- Laboratory of Molecular and Cellular Medicine, Faculty of Pharmaceutical Sciences Hokkaido University Sapporo Japan
-
- Shunsuke Ohnishi
- Laboratory of Molecular and Cellular Medicine, Faculty of Pharmaceutical Sciences Hokkaido University Sapporo Japan
-
- Ren Yamada
- Departments of Gastroenterology and Hepatology, Graduate School of Medicine Hokkaido University Sapporo Japan
-
- Masatsugu Ohara
- Departments of Gastroenterology and Hepatology, Graduate School of Medicine Hokkaido University Sapporo Japan
-
- Naoki Kawagishi
- Departments of Gastroenterology and Hepatology, Graduate School of Medicine Hokkaido University Sapporo Japan
-
- Mitsuteru Natsuizaka
- Departments of Gastroenterology and Hepatology, Graduate School of Medicine Hokkaido University Sapporo Japan
-
- Masato Nakai
- Departments of Gastroenterology and Hepatology, Graduate School of Medicine Hokkaido University Sapporo Japan
-
- Kenichi Morikawa
- Departments of Gastroenterology and Hepatology, Graduate School of Medicine Hokkaido University Sapporo Japan
-
- Ken Furuya
- Department of Gastroenterology and Hepatology Japan Community Health Care Organization (JCHO) Hokkaido Hospital Hokkaido Japan
-
- Kazuharu Suzuki
- Departments of Gastroenterology and Hepatology, Graduate School of Medicine Hokkaido University Sapporo Japan
-
- Takaaki Izumi
- Department of Gastroenterology and Hepatology Sapporo City General Hospital Hokkaido Japan
-
- Takashi Meguro
- Department of Gastroenterology and Hepatology Hokkaido Gastroenterology Hospital Hokkaido Japan
-
- Katsumi Terashita
- Department of Gastroenterology and Hepatology Japan Community Health Care Organization (JCHO) Sapporo Hokushin Hospital Hokkaido Japan
-
- Jun Ito
- Department of Gastroenterology and Hepatology The Hokkaido Medical Center Hokkaido Japan
-
- Tomoe Kobayashi
- Department of Gastroenterology and Hepatology Tomakomai City Hospital Hokkaido Japan
-
- Izumi Tsunematsu
- Touei Naika Clinic Hokkaido Japan
-
- Naoya Sakamoto
- Departments of Gastroenterology and Hepatology, Graduate School of Medicine Hokkaido University Sapporo Japan
抄録
<jats:title>Abstract</jats:title><jats:p>No prospective study on the efficacy of tenofovir alafenamide (TAF), a novel tenofovir prodrug, in preventing hepatitis B virus (HBV) reactivation has yet been reported. This multicenter prospective study enrolled HBV‐carriers who received TAF to prevent HBV reactivation before antitumor or immunosuppressive therapy, and patients with resolved HBV infection who experienced HBV‐reactivation and received TAF to prevent HBV reactivation‐related hepatitis. The efficacy of prophylactic TAF in preventing HBV reactivation and HBV reactivation‐related hepatitis was evaluated at 6 and 12 months after initiating TAF. Overall, 110 patients were administered TAF to prevent HBV reactivation or HBV reactivation‐related hepatitis. Three patients died owing to primary disease, whereas one patient was transferred to another hospital within 6 months after initiating TAF. Seven patients died due to primary disease, and five patients were transferred to another hospital within 12 months after initiating TAF. Therefore, 106 and 94 (77 patients with HBV infection, 17 with previous‐HBV infection) patients were evaluated at 6 and 12 months after initiating TAF, respectively. No patient experienced HBV reactivation, HBV reactivation‐related hepatitis, or treatment discontinuation due to HBV reactivation or adverse events of TAF after 6 and 12 months. TAF could effectively prevent HBV reactivation and HBV reactivation‐related hepatitis.</jats:p>
収録刊行物
-
- Journal of Medical Virology
-
Journal of Medical Virology 95 (2), 2023-01-10
Wiley
- Tweet
詳細情報 詳細情報について
-
- CRID
- 1360861705572330752
-
- ISSN
- 10969071
- 01466615
-
- データソース種別
-
- Crossref
- KAKEN